Astellas’ Xtandi nabs leg up over Johnson & Johnson’s Erleada with NICE prostate cancer win in UK
During the pandemic, Astellas’ oral prostate cancer drug Xtandi scored an interim nod in England as a “COVID friendly” way to treat men at home instead of in hospitals. With the pandemic easing there, cost watchdogs are backing the drug’s use for thousands of patients, offering the company an edge over its rival Johnson & Johnson. The National… Read More »
